Denmark-based LEO Pharma has agreed to acquire worldwide rights to dersimelagon, an oral melanocortin 1 receptor (MC1R) agonist for two ultra-rare photodermatoses, from Japan-based Tanabe Pharma for up to USD 435 million in combined upfront and near-term milestone payments, plus undisclosed downstream milestones and tiered royalties on net sales. The deal adds a Phase III-complete asset already under FDA review to LEO's rare dermatology pipeline, with regulatory approval now the principal near-term value trigger.
Dersimelagon is described by the company as designed to increase skin melanin, reducing sunlight penetration and protecting against phototoxic reactions in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP). The asset carries both US FDA Fast Track Designation and Orphan Drug Designation, and Tanabe submitted an NDA to the FDA in June 2026. In the global, randomized, double-blind, placebo-controlled Phase III INSPIRE study, Tanabe reported that dersimelagon increased average daily sunlight exposure before prodromal symptoms by a placebo-adjusted LS mean 23.19 minutes during Weeks 12–16 (p=0.004), increasing to 29.64 minutes at Week 16 in a supplementary analysis. Data were presented as a late-breaker at the 2026 American Academy of Dermatology Annual Meeting. If approved, the company said dersimelagon would represent the first oral therapy for EPP and XLP.
The only currently approved therapy for EPP is afamelanotide (Scenesse, Clinuvel Pharmaceuticals), a subcutaneous implant that shares the MC1R agonist mechanism. Dersimelagon's differentiation rests on oral administration, which addresses the patient and clinical burden associated with the implant format.
The USD 435 million figure bundles upfront and near-term payments without isolating the upfront component, a structure consistent with LEO's prior in-licensing deals. The company's 2025 acquisition of spesolimab (Spevigo) from Boehringer Ingelheim — a fully approved rare dermatology biologic — closed at USD 105 million upfront, providing a reference point for LEO's willingness to pay for late-stage rare skin disease assets. LEO's April 2026 acquisition of Replay's gene therapy platform for USD 50 million upfront, covering preclinical-stage rare skin disease programs, anchors the lower bound of the company's recent deal range.